Analysts Issue Forecasts for IceCure Medical FY2027 Earnings

IceCure Medical Ltd (NASDAQ:ICCM) – Analysts at Brookline Capital Management reduced their FY2027 EPS estimates for shares of IceCure Medical in a research report issued to clients and investors on Tuesday, November 26th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of $0.23 per share for the year, down from their previous forecast of $0.25. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.27) per share. Brookline Capital Management also issued estimates for IceCure Medical’s FY2028 earnings at $0.33 EPS.

ICCM has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and issued a $2.50 target price on shares of IceCure Medical in a report on Wednesday. Alliance Global Partners upgraded shares of IceCure Medical to a “strong-buy” rating in a report on Friday, November 1st.

IceCure Medical Price Performance

IceCure Medical stock opened at $0.83 on Thursday. IceCure Medical has a 52 week low of $0.48 and a 52 week high of $1.57. The company has a quick ratio of 2.54, a current ratio of 2.97 and a debt-to-equity ratio of 0.03. The firm’s 50-day simple moving average is $0.64 and its 200 day simple moving average is $0.73. The firm has a market capitalization of $37.96 million, a PE ratio of -2.77 and a beta of 0.48.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in IceCure Medical stock. Renaissance Technologies LLC acquired a new stake in shares of IceCure Medical Ltd (NASDAQ:ICCM) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned about 0.15% of IceCure Medical at the end of the most recent reporting period. 0.62% of the stock is currently owned by institutional investors.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.